European Medical Solutions

Report Publication Announcement • May 3, 2020

ASIT biotech postpones the publica3on of its 2019 annual report

Liège, Belgium, 3 May 2020, 6.00 pm (CEST) – ASIT biotech (ASIT - BE0974289218), a biopharmaceu.cal company focused on the research and development of breakthrough immunotherapy, announces that it is postponing to May 7, 2020 the publica.on of its 2019 annual report in accordance with government measures adopted due to the COVID-19 crisis. The ordinary general mee.ng should however be held at the date provided for in the company's ar.cles of associa.on, namely June 11, 2020.

***

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceu.cal company focused on the development and future commercializa.on of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innova.ve ASIT+™ technology plaQorm, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consis.ng of a unique mixture of highly purified natural allergen fragments in an op.mal size selec.on. This innova.on results in a short treatment, expected to improve pa.ent compliance and real-life effec.veness.

Further informa.on can be found at www.asitbiotech.com.

Follow us on LinkedIn

Company contact

Michel Baijot, CEO ASIT biotech Tel.: +32 2 264 03 90 investors@asitbiotech.com

Legal no3ce

This announcement is for informa.on purposes only and does not cons.tute an offer to sell or a solicita.on of an offer to buy or subscribe for the Company's shares in any jurisdic.on. This announcement does not cons.tute a prospectus. Any purchase of, subscrip.on for or applica.on for, Shares to be issued in connec.on with the intended offering should only be made on the basis of informa.on contained in the prospectus and any supplements thereto, as the case may be.

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guaranteeing future results. These forward-looking statements speak only as of the date of publica.on of this document. The Company expressly disclaims any obliga.on to update any forward-looking statements in this document, unless specifically required by law or regula.on.

Important informa3on

This press release is a transla.on of the original press release in French. In case of differences in transla.on or interpreta.on, it is the original press release in French who will prevail.